

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

SUPPLEMENTAL ANNOUNCEMENT ON GRANT OF SHARE OPTIONS

INVALID PREVIOUS GRANT OF SHARE OPTIONS

Reference is made to the announcement of LifeTech Scientific Corporation (the “**Company**”) published on 27 August 2018 (the “**Previous Announcement**”) in respect of the share options (the “**Share Options**” and each a “**Share Option**”) granted to certain eligible participants (the “**Grantees**”), to subscribe for a total of 5,400,000 ordinary shares with nominal value of US\$0.00000125 each (“**Shares**” and each a “**Share**”) in the share capital of the Company (the “**Previous Grant**”). Unless otherwise stated, terms used in this supplemental announcement shall have the same meanings as those defined in the Previous Announcement.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has been advised that pursuant to Rule 17.05 of the Listing Rules, the purported grant of Share Options shall take place no earlier than the date of the interim results announcement. As the Previous Grant was made on the same date as the date of publication of the 2018 interim results announcement of the Company, the Previous Grant was invalid and cancelled under the Scheme.

NEW GRANT OF SHARE OPTIONS

The following announcement is made pursuant to Rule 17.06A of the Listing Rules.

The Board hereby announces that after the cancellation of the Previous Grant, on 29 August 2018, 5,400,000 Share Options to subscribe for a total of 5,400,000 Shares in the share capital of the Company were granted to Grantees, subject to acceptances of the Grantees, under the Company’s Scheme. Such Shares represent approximately 0.12% of the issued share capital of the Company as at the date of this announcement and approximately 0.12% of the issued share capital on a fully diluted basis.

Details of the Share Options are set out as follows:

- Date of grant : 29 August 2018 (the “**New Grant Date**”)
- Exercise price of the Share Options granted : HK\$2.060 per Share, which represents the highest of:
- (i) the closing price of HK\$2.020 per Share on the New Grant Date, i.e. 29 August 2018;
 - (ii) the average closing price of HK\$2.060 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the date of grant;
 - (iii) the nominal value of a Share.
- Number of Share Options granted : 5,400,000 (each Share Option shall entitle the holder thereof to subscribe for one Share)
- Validity and exercise period of the Share Options : 10 years from the New Grant Date with the following exercise periods:
- (i) First tranche (20% of the Share Options) is exercisable from 29 August 2019 to 28 August 2028;
 - (ii) Second tranche (20% of the Share Options) is exercisable from 29 August 2020 to 28 August 2028;
 - (iii) Third tranche (20% of the Share Options) is exercisable from 29 August 2021 to 28 August 2028;
 - (iv) Fourth tranche (20% of the Share Options) is exercisable from 29 August 2022 to 28 August 2028;
 - (v) Fifth tranche (20% of the Share Options) is exercisable from 29 August 2023 to 28 August 2028.

None of the Grantees or their respective associates (as defined in the Listing Rules) is a Director, chief executive or substantial shareholder of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer and
Executive Director*

Hong Kong, 29 August 2018

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. ZHANG Deyuan and Mr. LIU Jianxiong being executive Directors of the Company; Mr. JIANG Feng being non-executive Directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Luming and Mr. WANG Wansong being independent non-executive Directors of the Company.